

NCT02431559 Raw comparison:

Summary:
CHIA has 47 criteria while your personal folder has 66 criteria
Total found criteria: 36/47
Total not Found: 11/47
Total Extra: 19
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Subjects must have recurrent or persistent         │ Subjects must have had recurrent or persistent     │
│ platinum-resistant epithelial ovarian fallopian    │ platinum-resistant epithelial ovarian fallopian    │
│ tube or primary peritoneal carcinoma with          │ tube or primary peritoneal carcinoma with          │
│ measureable disease (as defined by RECIST 1 1 )    │ measurable disease (as defined by the Response     │
│ after first or second line platinum-based          │ Evaluation Criteria in Solid Tumors \[RECIST\] 1 1 │
│ chemotherapy for which treatment with PLD is       │ ) after first or second line platinum-based        │
│ indicated Platinum-based therapy is defined as     │ chemotherapy for which treatment with PLD was      │
│ treatment with carboplatin cisplatin or another    │ indicated Platinum-based therapy was defined as    │
│ organoplatinum compound Platinum-resistant is      │ treatment with carboplatin cisplatin or another    │
│ defined as having a platinum-free interval (PFI)   │ organoplatinum compound Platinum-resistant was     │
│ of < 12 months after first- or second-line         │ defined as having a platinum-free interval of \<   │
│ platinum-based chemotherapy or having disease      │ 12 months after first- or second-line platinum-    │
│ progression while receiving second-line platinum-  │ based chemotherapy or having disease progression   │
│ based chemotherapy                                 │ while receiving second-line platinum-based         │
│                                                    │ chemotherapy                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects are allowed to have received but are not  │ Subjects were allowed to have received but were    │
│ required to have received                          │ not required to have received                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ biologic therapy (e g bevacizumab) as part of      │ biologic therapy (e g bevacizumab) as part of      │
│ their primary treatment regimen or part of their   │ their primary treatment regimen or part of their   │
│ treatment for management of recurrent or           │ treatment for management of recurrent or           │
│ persistent disease                                 │ persistent disease                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Histologic documentation of the original primary   │ Histologic documentation of the original primary   │
│ tumor                                              │ tumor                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Documented radiographic disease progression < 12   │ Documented radiographic disease progression \< 12  │
│ months after the last dose of first- or second-    │ months after the last dose of first- or second-    │
│ line platinum-based chemotherapy                   │ line platinum-based chemotherapy                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects in Phase 2 must have disease amenable to  │ Subjects in Phase 2 must have had disease amenable │
│ biopsy and must be willing to undergo pre- and     │ to biopsy and must have been willing to undergo    │
│ post-treatment tumor biopsies Optional for Phase 1 │ pre- and post-treatment tumor biopsies Optional    │
│                                                    │ for Phase 1                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Note archival tissue will be requested for all     │ Note archival tissue was requested for all         │
│ subjects preferably from primary tumor site prior  │ subjects preferably from primary tumor site prior  │
│ to cancer treatment however archival tissue is not │ to cancer treatment however archival tissue was    │
│ a requirement for study entry                      │ not a requirement for study entry                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Laboratory parameters for vital functions should   │ Laboratory parameters for vital functions should   │
│ be in the normal range Laboratory abnormalities    │ have been in the normal range Laboratory           │
│ that are not clinically significant are generally  │ abnormalities that were not clinically significant │
│ permitted except for the following laboratory      │ were generally permitted except for the following  │
│ parameters which must be within the ranges         │ laboratory parameters which must have been within  │
│ specified regardless of clinical significance      │ the ranges specified regardless of clinical        │
│                                                    │ significance                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hemoglobin ≥ 9 g/dL                                │ Hemoglobin ≥ 9 g/dL                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Neutrophil count ≥ 1 5 x 109/L                     │ Neutrophil count ≥ 1 5 x 10\^9/L                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Platelet count ≥ 100 000/mm3                       │ Platelet count ≥ 100 000/mm\^3                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum creatinine ≤ 1 5x Institutional Upper Limit  │ Serum creatinine ≤ 1 5 x institutional upper limit │
│ of Normal (ULN) or Creatinine Clearance ≥ 50       │ of normal (ULN) or creatinine clearance ≥ 50       │
│ mL/min (by Cockcroft-Gault formula)                │ mL/min (by Cockcroft-Gault formula)                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum bilirubin ≤ 1 2 mg/dL                        │ Serum bilirubin ≤ 1 2 mg/dL                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Alkaline phosphatase ≤ 2 5 x ULN                   │ Alkaline phosphatase ≤ 2 5 x ULN                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Age ≥18 years                                      │ Age ≥18 years                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Able and willing to give valid written informed    │ Able and willing to give valid written informed    │
│ consent                                            │ consent                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Body weight > 30 kg                                │ Body weight \> 30 kg                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects with platinum-refractory disease defined  │ Subjects with platinum-refractory disease defined  │
│ as disease progression while receiving first line  │ as disease progression while receiving first line  │
│ platinum-based therapy                             │ platinum-based therapy                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Clinically significant persistent immune-related   │ Clinically significant persistent immune-related   │
│ adverse events following prior therapy             │ adverse events following prior therapy             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects with history or evidence upon physical    │ Subjects with history or evidence upon physical    │
│ examination of CNS disease including primary brain │ examination of central nervous system disease      │
│ tumor seizures not controlled with standard        │ including primary brain tumor seizures not         │
│ medical therapy any brain metastases or within six │ controlled with standard medical therapy any brain │
│ months prior to Day 1 of this study history of     │ metastases or within 6 months prior to Day 1 of    │
│ cerebrovascular accident (CVA stroke) transient    │ this study history of cerebrovascular accident     │
│ ischemic attack (TIA) or subarachnoid hemorrhage   │ (stroke) transient ischemic attack or subarachnoid │
│                                                    │ hemorrhage                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects with clinically significant               │ Subjects with clinically significant               │
│ cardiovascular disease This includes               │ cardiovascular disease This included               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Myocardial infarction or unstable angina within 6  │ Myocardial infarction or unstable angina within 6  │
│ months prior to Day 1 of the study                 │ months prior to Day 1 of the study                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of serious ventricular arrhythmia (i e     │ History of serious ventricular arrhythmia (i e     │
│ ventricular tachycardia or ventricular             │ ventricular tachycardia or ventricular             │
│ fibrillation) or cardiac arrhythmias requiring     │ fibrillation) or cardiac arrhythmias requiring     │
│ anti-arrhythmic medications except for atrial      │ anti-arrhythmic medications except for atrial      │
│ fibrillation that is well controlled with anti-    │ fibrillation that is well controlled with anti-    │
│ arrhythmic medication                              │ arrhythmic medication                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ New York Heart Association (NYHA) Class II or      │ New York Heart Association Class II or higher      │
│ higher congestive heart failure                    │ congestive heart failure                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Grade 2 or higher peripheral ischemia except for   │ Grade 2 or higher peripheral ischemia except for   │
│ brief (< 24 hrs) episodes of ischemia managed non- │ brief (\< 24 hours) episodes of ischemia managed   │
│ surgically and without permanent deficit           │ non-surgically and without permanent deficit       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of pneumonitis or interstitial lung        │ History of pneumonitis or interstitial lung        │
│ disease                                            │ disease                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active suspected or prior documented autoimmune    │ Active suspected or prior documented autoimmune    │
│ disease (including inflammatory bowel disease      │ disease (including inflammatory bowel disease      │
│ celiac disease Wegner's granulomatosis active      │ celiac disease Wegner's granulomatosis active      │
│ Hashimoto's thyroiditis rheumatoid arthritis lupus │ Hashimoto's thyroiditis rheumatoid arthritis lupus │
│ scleroderma and its variants multiple sclerosis    │ scleroderma and its variants multiple sclerosis    │
│ myasthenia gravis) Vitiligo type I diabetes        │ myasthenia gravis) Vitiligo type I diabetes        │
│ mellitus residual hypothyroidism due to autoimmune │ mellitus residual hypothyroidism due to autoimmune │
│ condition only requiring hormone replacement       │ condition only requiring hormone replacement       │
│ psoriasis not requiring systemic treatment or      │ psoriasis not requiring systemic treatment or      │
│ conditions not expected to recur in the absence of │ conditions not expected to recur in the absence of │
│ an external trigger are permitted                  │ an external trigger were permitted                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Other malignancy within 2 years prior to Day 1 of  │ Other malignancy within 2 years prior to Day 1 of  │
│ the study except for those treated with surgical   │ the study except for those treated with surgical   │
│ intervention only                                  │ intervention only                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects with clinical symptoms or signs of        │ Subjects with clinical symptoms or signs of        │
│ gastrointestinal obstruction and/or who require    │ gastrointestinal obstruction and/or who required   │
│ drainage gastrostomy tube and/or parenteral        │ drainage gastrostomy tube and/or parenteral        │
│ hydration or nutrition                             │ hydration or nutrition                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of severe allergic reactions to any        │ History of severe allergic reactions to any        │
│ unknown allergens or components of the study drugs │ unknown allergens or components of the study drugs │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Other serious illnesses (e g serious infections    │ Other serious illnesses (e g serious infections    │
│ requiring antibiotics bleeding disorders)          │ requiring antibiotics bleeding disorders)          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Prior treatment in any other interventional        │ Prior treatment in any other interventional        │
│ clinical trial within 4 weeks prior to Day 1 of    │ clinical trial within 4 weeks prior to Day 1 of    │
│ the study                                          │ the study                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Mental impairment that may compromise compliance   │ Mental impairment that may have compromised        │
│ with the requirements of the study                 │ compliance with the requirements of the study      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Lack of availability for immunological and         │ Lack of availability for immunological and         │
│ clinical follow-up assessment                      │ clinical follow-up assessment                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any condition that in the clinical judgment of the │ Any condition that in the clinical judgment of the │
│ treating physician is likely to prevent the        │ treating physician was likely to prevent the       │
│ subject from complying with any aspect of the      │ subject from complying with any aspect of the      │
│ protocol or that may put the subject at            │ protocol or that may have put the subject at       │
│ unacceptable risk                                  │ unacceptable risk                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of allogeneic organ transplant             │ History of allogeneic organ transplant             │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                                │
╞════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ one additional cytotoxic regimen and/or PARP inhibitor for management of recurrent or persistent   │
│ disease                                                                                            │
├────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ ECOG performance status of 0 or 1                                                                  │
├────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ AST/ALT ≤ 2 5 x ULN                                                                                │
├────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Prior exposure to doxorubicin PLD or any other anthracycline motolimod and other TLR agonists      │
│ MEDI4736 or checkpoint inhibitors such as anti-CTLA4 and anti-PD1/anti-PD-L1 antibodies            │
├────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Resisted hypertension                                                                              │
├────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Baseline ejection fraction ≤ 50% as assessed by echocardiogram or MUGA                             │
├────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Known immunodeficiency or HIV Hepatitis B or Hepatitis C positivity                                │
├────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Women who are breastfeeding or pregnant as evidenced by positive serum pregnancy test              │
├────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects unwilling to use acceptable methods of contraception                                      │
├────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ -Female subjects should refrain from breastfeeding throughout this period                          │
├────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Subjects must not donate blood while on study and for at least 90 days following the last MEDI4736 │
│ treatment                                                                                          │
╘════════════════════════════════════════════════════════════════════════════════════════════════════╛



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                              │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Subjects must not have donated blood while on study and for at least 90 days following the last      │
│ durvalumab treatment                                                                                 │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Women of childbearing potential who were found to be pregnant as evidenced by positive serum         │
│ pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin) or  │
│ nursing NOTE Pregnancy tests were not required for subjects who were not of childbearing potential   │
│ as defined in #17                                                                                    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ A highly effective method of contraception was defined as one that results in a low failure rate (i  │
│ e less than 1% per year) when used consistently and correctly Note that some contraception methods   │
│ were not considered highly effective (e g male or female condom with or without spermicide female    │
│ cap diaphragm or sponge with or without spermicide non-copper containing intrauterine device         │
│ progestogen-only oral hormonal contraceptive pills where inhibition of ovulation is not the primary  │
│ mode of action \[excluding Cerazette/desogestrel which is considered highly effective\] and          │
│ triphasic combined oral contraceptive pills)                                                         │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ one additional cytotoxic regimen and/or poly adenosine diphosphate-ribose polymerase inhibitor for   │
│ management of recurrent or persistent disease                                                        │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Baseline ejection fraction ≤ 50% as assessed by echocardiogram or multiple-gated acquisition         │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2 5 x ULN                          │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must be FEMALE                                                                                       │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Resistant hypertension                                                                               │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Females ≥ 50 years of age were considered post-menopausal if they had been amenorrheic for 12 months │
│ or more following cessation of all exogenous hormonal treatments had radiation-induced menopause     │
│ with last menses \> 1 year ago had chemotherapy-induced menopause with last menses \> 1 year ago or  │
│ underwent surgical sterilization (bilateral oophorectomy bilateral salpingectomy or hysterectomy)    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Females of childbearing potential were defined as those who were not surgically sterile (i e         │
│ bilateral tubal ligation bilateral oophorectomy or complete hysterectomy) or post-menopausal         │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ NOTE For the standard of care PLD (Doxil® Caelyx®) the package insert advises females of             │
│ reproductive potential to use effective contraception during and for 6 months after last treatment   │
│ with the drug Therefore all subjects of childbearing potential on this study should have continued   │
│ contraception use for 6 months after the last PLD administration                                     │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Known immunodeficiency or human immunodeficiency virus Hepatitis B or Hepatitis C positivity         │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1                               │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Prior exposure to doxorubicin PLD or any other anthracycline motolimod and other toll-like receptor  │
│ agonists durvalumab or checkpoint inhibitors such as anti-cytotoxic T-lymphocyte-associated          │
│ antigen-4 (CTLA-4) and anti-programmed cell death-1 (PD-1)/anti-programmed cell death ligand-1       │
│ (PD-L1) antibodies                                                                                   │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Female subjects of childbearing potential who were sexually active with a nonsterilized male partner │
│ must have used at least one highly effective method of contraception from screening and must have    │
│ agreed to continue using such precautions for 90 days after the final dose of investigational        │
│ product (durvalumab) Male partners of a female subject must have used male condom plus spermicide    │
│ throughout this period (from screening and for 90 days after subject's receipt of the final dose of  │
│ investigational product) Cessation of birth control after this point should have been discussed with │
│ a responsible physician Not engaging in sexual activity for the total duration of the trial and the  │
│ drug washout period was an acceptable practice however periodic abstinence the rhythm method and the │
│ withdrawal method were not acceptable methods of birth control                                       │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Females were considered post-menopausal if they had been amenorrheic for 12 months without an        │
│ alternative medical cause The following age-specific requirements applied                            │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                    │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Females \< 50 years of age were considered post-menopausal if they had been amenorrheic for 12       │
│ months or more following cessation of exogenous hormonal treatments and if they had luteinizing      │
│ hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or  │
│ underwent surgical sterilization (bilateral oophorectomy or hysterectomy)                            │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Female subjects should have refrained from breastfeeding throughout the period described above       │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛